Previous feasibility studies and experiences in both TUBA and WISP have demonstrated that high-risk individuals are not willing to be randomized.12 13 Therefore, the investigators from these major studies have collaborated to design an international prospective preference study to evaluate the novel treatment as an alternative to the standard treatment in participants with a BRCA1/2 pathogenic variant with respect to tubo-ovarian cancer incidence. The gene discussed is BRCA1; the disease is ovarian cancer.